Progress in the research of Radix Astragali in treating chronic heart failure: Effective ingredients, dose-effect relationship and adverse reaction-Reference-Cited by-同舟云学术

Progress in the research of Radix Astragali in treating chronic heart failure: Effective ingredients, dose-effect relationship and adverse reaction

Published:2011-06 Issue:6 Volume:17 Page:473-477
ISSN:1672-0415
Container-title:Chinese Journal of Integrative Medicine
language:en
Short-container-title:Chin. J. Integr. Med.

Author:

Lu Shu,Chen Ke-ji,Yang Qing-you,Sun Hui-ru

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Complementary and alternative medicine,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s11655-011-0756-5.pdf

Reference39 articles.

1. National Committee of Pharmacopoeia. Pharmacopoeia of the People’s Republic of China. 2000 edtion. Beijing: China Medical Science and Technology Press; 2010:283–284.

2. Li R, Fu TJ, Ji QY, Ding LS, Peng SL. A study of the roots of Astragalus Mongholicus and Astragalus Membranaceus by high performance liquid chromatography-mass spectrometry. Chin J Anal Chem (Chin) 2005;33:1676–1680.

3. Duan YM, Xie D. Studies on the chemical components of Astragalus membranaceus and the method of determinating effectual constituent—astragaloside IV. Chin J Veterinary Drug (Chin) 2005;39:35–38.

4. Liang LJ, Zhao KJ, Tu PF, Jiang Y. Simultaneous determination of 4 kinds of flavonoids in Radix Astragali by HPLC. China Pharm (Chin) 2010;21:1385–1387.

5. Liu Y, Ma XX, Chen HB, Tu GZ, He JM, Zhao YY. Chemical constituents of Hedysarum Gmelinii. J Chin Pharm Sci (Chin) 2005;14:75–78.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism of XiJiaQi in the treatment of chronic heart failure: Integrated analysis by pharmacoinformatics, molecular dynamics simulation, and SPR validation;Computers in Biology and Medicine;2023-11

2. Astragaloside IV derivative HHQ16 ameliorates infarction-induced hypertrophy and heart failure through degradation of lncRNA4012/9456;Signal Transduction and Targeted Therapy;2023-10-19

3. Review on the protective mechanism of astragaloside IV against cardiovascular diseases;Frontiers in Pharmacology;2023-05-11

4. Astragaloside IV Inhibits NLRP3 Inflammasome-Mediated Pyroptosis via Activation of Nrf-2/HO-1 Signaling Pathway and Protects against Doxorubicin-Induced Cardiac Dysfunction;Frontiers in Bioscience-Landmark;2023-03-03

5. Bioinformatics and In Silico Findings Uncover Bio-Targets of Calycosin Against Heart Failure and Diabetes Mellitus;Frontiers in Endocrinology;2022-07-08